Fri, Jul 25, 2014, 3:09 PM EDT - U.S. Markets close in 51 mins.

Recent

% | $
Click the to save as a favorite.

Amarin Corporation plc Message Board

  • investrforever investrforever Nov 19, 2012 6:44 PM Flag

    Difference between NCE (5 year) exclusivity and 3 year exclusivity

    When a new chemical entity (NCE) is first approved as a drug under a New Drug Application (NDA), the sponsor is entitled to a five year exclusivity period that bars the submission of any generic drug application for a product that contains that NCE. There are two types of generic drug applications: Abbreviated New Drug Applications (ANDA); and the so-called 505(b)(2) NDA. With both types of applications, approval of the competing product relies upon FDA’s prior approval of a drug containing the NCE as being safe and effective. An exception allows filing of a generic application as early as four years after NCE approval if the competitor challenges the validity or applicability of a patent on the NCE. However, under the complex rules governing generic drug patent challenges, and in light of the two or more year FDA review time for ANDAs, final generic approval is usually not possible for at least seven years post-NCE approval, or longer.

    Another regulatory exclusivity applies when a sponsor obtains FDA approval of certain changes to an already approved drug, eg, a new indication, a new dosing regimen, a new patient population, a switch to over-the-counter marketing status, or other labelling changes. If new clinical studies, conducted or sponsored by the applicant, are deemed by FDA to be essential to the approval of the change, the sponsor is awarded a three-year exclusivity period for the approved change. But, unlike the five year NCE exclusivity, the three year exclusivity only bars FDA approval of an ANDA or 505(b)(2) NDA for the same change, and once the three year exclusivity period expires, pending generic applications for the change may be approved immediately. Moreover, in many instances, a generic version can still be approved using the old labelling – ie, by carving out the exclusive labelling language – before the three year exclusivity expires. Given the liberal generic substitution rules in most states, this exclusivity is often considered to be of limited value. Thus, sophisticated companies and their FDA counsel have pursued regulatory strategies that can enhance the power of the three year exclusivity to prevent or delay FDA approval of generic versions that use the old, unprotected labelling. These strategies have been vigorously opposed by generic manufacturers and patients groups, and have a mixed record of success.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AMRN
1.50-0.07(-4.46%)3:09 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.